Nicole Mastacouris, Rachel Tannenbaum, Andrew Strunk, Jonathan Koptyev, Pim Aarts, Raed Alhusayen, Falk G Bechara, Farida Benhadou, Vincenzo Bettoli, Alain Brassard, Debra Brown, Siew Eng Choon, Patricia Coutts, Dimitri Luz Felipe da Silva, Steven Daveluy, Robert P Dellavalle, Veronique Del Marmol, Lennart Emtestam, Kurt Gebauer, Ralph George, Evangelos J Giamarellos-Bourboulis, Noah Goldfarb, Iltefat Hamzavi, Paul G Hazen, Barbara Horváth, Jennifer Hsiao, John R Ingram, Gregor B E Jemec, Joslyn S Kirby, Michelle A Lowes, Angelo V Marzano, Lukasz Matusiak, Haley B Naik, Martin M Okun, Hazel H Oon, Lauren A V Orenstein, So Yeon Paek, José C Pascual, Pablo Fernandez-Peñas, Barry I Resnik, Christopher J Sayed, Linnea Thorlacius, Hessel H van der Zee, Kelsey R van Straalen, Amit Garg
IMPORTANCE: Although several clinician- and patient-reported outcome measures have been developed for trials in hidradenitis suppurativa (HS), there is currently no consensus on which measures are best suited for use in clinical practice. Identifying validated and feasible measures applicable to the practice setting has the potential to optimize treatment strategies and generate generalizable evidence that may inform treatment guidelines. OBJECTIVE: To establish consensus on a core set of clinician- and patient-reported outcome measures recommended for use in clinical practice and to establish the appropriate interval within which these measures should be applied...
September 27, 2023: JAMA Dermatology